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ABSTRACT
Introduction: Myeloma multiplex is defined by the presence of monoclonal plasma cell population in the bone marrow>10%,M protein in the 
serum and/or urine ,and clinical evidence of end organ damage like hypercalcemia ,renal failure, anemia, or bone lesions. In the most hematologic 
malignancies the role of induction treatment is to achieve complete remission (CR). Thalidomide became a new therapeutic approach but use of 
Thalidomide as a single agent or combination with steroids or chemotherapy is associated with several side effects like deep vein thrombosis (DVT), 
peripheral neuropathy (PN), constipation, somnolence, pyrexia, pain, fatigue osteonecrosis of jaw, and teratogenicity that is the most worrying 
adverse event. Risk of appearance of DVT increased if we use combination of Thalidomide plus Dexamethasone plus cytotoxic chemotherapy 
such Cyclophosphamide. >30% DVT usually occurs during the first months of treatment and is more frequent in newly diagnosed patients with 
a high tumor burden. The second side effect is peripheral neuropathy (PN) which occurs in 50% of patients with MM treated with Thalidomide 
plus Dexamethasone and chemotherapy. Patients and methods: Eighty patients of both sexes (43 males and 37 females) at the age of 31-81 
(median range 58 years) with MM, were treated–one group with combinations of Thalidomide plus Dexamethasone plus Cyclophosphamide 
(CyThalDex) 4 cycle( >4months), and the other group with Thalidomide plus Dexamethasone plus Melphalan (MPT), ( >4month) and third 
group with high dose of chemotherapy and continue with ThalDex (TD), the fourth group with CyThalDex, > than 5 cycles, and the fifth group 
with ThalDex (TD) only. Results: It is obvious while myelo-suppression is very rare, the incidence of nonhematologic side effects is high and 
dose dependent. Eight ( or 10% ) patients that developed DVT and CVI were initially treated with antiaggregation therapy of Aspirin 100mg 
per day, but those that already developed were treated with low dose of Heparin 40000 iE per day in ten days and continued with oral antico-
agulans therapy. However, besides the given therapy in four (or 5 %) patients there was exitus letalis. PN was developed in twentyone patients ( 
or 26.25%) from the total number of patients treated with Thalidomide, in ten patients the dosage of Thalidomide was decreased to 50mg per 
day, in one patient with Epi attacks it was interrupted and the other was with paresis n.occulomotorius and n.abducens. Conclusions: Patients 
treated with thalidomide have an increased risk of arterial thromboembolism, including myocardial infarction and cerebrovascular events, in 
addition to the established risk of venous thromboembolism, but most patients who presenting DVT or some of thromboembolic events have 
had identifiable risk factors. The prolonged exposure to Thalidomide seems to induce resistance of MM reducing overall survival (OS). We must 
evaluate consolidation and maintenance therapies with Thalidomide, determinate which regimens provide a highness benefit with favorable side 
effect profiles in specific subgroups of patients.
Key words: Myeloma multiplex (MM), Deep Vein Thrombosis (DVT), Peripheral Neuropathy (PN), Thalidomide.
1. INTRODUCTION
Myeloma multiplex is defined by the presence of monoclonal 
plasma cell population in the bone marrow >10% M protein 
in the serum and/or urine, and clinical evidence of end organ 
damage like hypercalcemia, renal failure, anemia, or bone le-
sions (1, 2). In the most hematologic malignancies the role of 
induction treatment is to achieve complete remission (CR). 
In MM this has been possible only with the introduction of 
high-dose therapy plus autologous stem cell transplantation 
(ASCT) in patients eligible for transplantation. At the end the 
clinical results from many studies were poorest, CR was possible 
only in 20-40% and 40%-55% CR/VGPR (very good partial 
remission). Of course treatment of MM patients ineligible for 
transplantation, conventional therapy was consist of alkylat-
ing–based regimens mainly melphalane plus prednisolone (MP) 
or dexamethasone, with these regimens CR rate was <5% with 
median survival of approximately 3 years (3, 4). The introduc-
tion of novel agents in the induction treatment is changing 
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this story. Thalidomide became a new therapeutic approach 
and its derivates such lenalidomide, with their antiangioge-
netic properties via inhibition of vascular endothelial growth 
factor (VEGF) and β–fibroblast growth factor (FGF), directly 
inhibits growth and survival of myeloma cells. Of course we 
didn’t ignore immunomodulatory properties like blocks the 
activation of nuclear factor–κβ and inhibits the production of 
proinflammatory citokines and increase antimyeloma immunity 
by stimulating T lymphocytes and natural killer cells (2, 5, 6). 
Clinical efficacy of thalidomide is evident: in relapsed/refractory 
MM approximately 45% induces objective response, in newly 
diagnosed patients with MM is obvious CR or VGPR (4). But 
use of thalidomide as a single agent or combination with steroids 
or chemotherapy is associated with several side effects like deep 
vein thrombosis (DVT), peripheral neuropathy (PN) charac-
terized by numbness, paresthesia or pain in the hands or in the 
feet or legs, death from DVT, or embolio pulmonum (EP), the 
most serious and others like constipation, somnolence, pyrexia, 
pain, fatigue osteonecrosis of jaw (7, 8, 9). Teratogenicity is the 
most worrying adverse event and although MM usually affects 
postmenopausal women, special programs have been designed 
to avoid drug exposure in women of child-bearing potential. 
The incidence of DVT with Thalidomide alone is 3-4% in new 
MM, and 2-4% more in refractory disease (10). The incidence of 
DVT and PN were 12% and 30% in the MPT. But the addition 
of dexamethasone, especially at high dose markedly increases 
the risk, specially in those patients with new disease. In newly 
diagnosed MM, incidence of DVT, treated with Thal/Dex is 
14-26% and 2-8% more in those with relapsed or refractory 
disease without thromboprophylaxis (3, 4). Risk of appearance 
of DVT increased if we use combination of Thalidomide plus 
Dexamethasone plus cytotoxic chemotherapy such Cyclophos-
phamide. >30% DVT usually occurs during the first months 
of treatment and is more frequent in newly diagnosed patients 
with a high tumor burden (11, 12). The second side effect is 
peripheral neuropathy (PN) which occurs in 50% of patients 
with MM treated with Thalidomide and Dexamethasone and 
chemotherapy (4, 7, 8). Constipation occurs 100%, sedation 
87% and skin lesion but for these side effects patients developed 
tolerance. Very important is the role of Thalidomide in relapsed 
or refractory MM patients who has show courage results (7).
2. MATERIAL AND METHODS
Eighty patients of both sexes (43 males and 37 females) at the 
age of 31-81 (median range 58 years) with MM were treated one 
group with combinations of Thalidomide plus Dexamethasone 
plus Cyclophosphamide (CyThalDex) 4 cycle( >4months), and 
the other group with Thalidomide plus Dexamethasone plus 
Melphalan (MPT), (>4month) and third group with high 
dose of chemotherapy and continue with ThalDex (TD), the 
fourth group with CyThalDex, > than 5 cycles, and the fifth 
group with ThalDex (TD) only. Patients have been evaluated 
for every check-up in our Daily hospital. Patients were started 
with Thalidomide 100mg/per day with or without Dex and 
chemotherapy. During the course of therapy, patients were 
monitored every 15 days and all possible adverse effects were 
evidenced in checklist.
Those patients that developed life threatening complica-
tion like DVT or EP or Thrombosis of sinus saggitalis were 
interrupted with treatment with Thalidomide but from the 
total number of patients this complication was shown in small 
number of patients. With those patients that developed PN as 
a complication from Thalidomide, the application of the dos-
age was decreased to 50mg per day in one temporary period, 
when the MM patient’s parameters allowed that. Our study 
of patients presents eight patients ( or 10% ) developed DVT. 
Twentyone patients (or 26.25%) developed PN (one patient of 
the researched group developed paresis of n.occulomotorius 
et n.abducens and one patient developed Epi attacks). Five (5) 
patients (or 6.25%) developed both DVT and PN. Four patients 
(or 5 %) ended with exitus letalis from which two (or 2.5 %) of 
them with unexpected death from Embolio pulmonum (EP), 
one patient (or 1.25% ) from Thrombosis of sinus sagitalis and 
one patient (or 1.25% ) from unknown cause. One patient was 
treated successfully after the complication of EP. Other com-
plications that were developed in our group of patients after the 
application of Thalidomide were swollen knives in four patients 
(or 5%), obstipation in seventytwo patients (or 90%), vomitus 
and sickness and primary intolerableness of medication shown 
in four patients (or 5%), one patient showed reactivation of B 
Hepatitis and one patient showed secondary carcinoma in vesica 
urinaria (Table 1). 
The time of application of Thalidomide didn’t correlate 
with the aspect of DVT. Those patients who were eligible for 
autologous transplantation, with or without side effects of Tha-
lidomide administration, were transplanted, but those patients 
who were ineligible for auto transplantation (coexisting of co-
morbidity and elderly patients) were treated only with TD. The 
age of patients and organ damage predicted the clinical response 
in MM patients, but they didn’t predict the side effects of novel 
agents. So the question was: What is the optimal duration of 
induction treatment with novel agents?
3. RESULTS
It is obvious while myelo-suppression is very rare, the inci-
dence of nonhematologic side effects is high and dose dependent. 
Eight (or 10% ) patients that developed DVT and CVI were 
initially treated with antiaggregation therapy of Aspirin 100mg 
per day, but those that already developed were treated with low 
dose of Heparin 40000 iE per day in ten days and continued 
with oral anticoagulans therapy. However, besides the given 
therapy in four (or 5 %) patients there was exitus letalis. PN 
Therapy No of patients Percent DVT PN EP CVI DVT plus PN
4 cycle CyThalDex 18 22.5 5 2 3 1
MPT 18 22.5 4
High dose of chemo plus TD 10 12.5 1 1
> than 5 cycles CyThalDex 20 25 1 11 1 4
TD 14 17.5 1 3
Total 80 100 8 21 3 1 5
Table 1. Correlation of use ofThalidomide  with the aspect of DVT
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was developed in twentyone patients (or 26.25%) from the total 
number of patients treated with Thalidomide, in ten patients 
the dosage of Thalidomide was decreased to 50mg per day, in 
one patient with Epi attacks it was interrupted and the other 
was with paresis n. occulomotorius and n. abducens.
4. DISCUSSION AND CONCLUSION
Patients treated with thalidomide have an increased risk of 
arterial thromboembolism, including myocardial infarction 
and cerebrovascular events, in addition to the established risk 
of venous thromboembolism, but most patients who presenting 
DVT or some of thromboembolic events have had identifiable 
risk factors. Action should be taken to minimize all modifi-
able risk factors for thromboemboling events (e.g. smoking, 
hypertension and hyperlipidemia) and of course application 
of thromboprophylaxis in patients suitable for treatment with 
thalidomide (13, 14, 15).
Thalidomide seems to be good choice for patients with MM 
who are eligible for autologous transplantation, considering 
their toxicity profile (1). Firstly, PN and Thalidomide, the lack 
of correlation between cumulative dose and outcome, a limited 
administration is suggested. The choice of first relapse treat-
ment will probably depend on the previous treatments and on 
the true evaluation of the risk/benefit ratio in function of the 
toxicity profile of Thalidomide. Thalidomide has an excellent 
role in consolidation phase of this chronic disease like MM, 
rather than maintenance, but with lower dose of Thalidomide 
and for a limited period. Moreover, a prolonged exposure to 
Thalidomide seems to induce resistance of MM reducing over-
all survival (OS). We must evaluate consolidation and mainte-
nance therapies with Thalidomide, determinate which regimens 
provide a highness benefit with favorable side effect profiles in 
specific subgroups of patients.
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